We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
Read MoreHide Full Article
Key Takeaways
Keytruda made up over half of MRK's pharma sales in H1 2025, reaching $15.16B, up 7% year over year.
Merck eyes H2 growth from Keytruda, Animal Health, Winrevair, and Capvaxive, offset by weaker Gardasil sales.
MRK is developing combos, an mRNA vaccine with Moderna, and a subcutaneous Keytruda to boost growth.
Merck’s (MRK - Free Report) strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s pharmaceutical sales during the first half of 2025.
Keytruda, approved for several types of cancers, has played an instrumental role in driving Merck’s steady revenue growth over the past few years.
Keytruda generated sales of $15.16 billion in the first half of 2025, up almost 7% year over year. The drug remains a key driver of Merck’s top-line growth. Our model estimates full-year 2025 sales for Keytruda to be $32.2 billion, suggesting an increase of 9.2% year over year.
The drug’s sales are gaining from rapid uptake across earlier-stage indications, mainly early-stage non-small cell lung cancer. Continued strong momentum in metastatic indications is also boosting sales growth. The company expects continued growth from Keytruda, particularly in early lung cancer.
Per management, Keytruda will remain a key revenue driver for the company in the second half of 2025, along with the Animal Health business and new product launches like Winrevair and Capvaxive. However, weaker Gardasil sales in China and Japan will partly offset gains.
MRK Eyes Keytruda's Long-Term Growth Amid Upcoming Patent Loss
With Keytruda set to face patent loss in 2028, Merck is working on different strategies to drive its long-term growth. The company is advancing innovative immuno-oncology combinations, such as pairing Keytruda with LAG3 and CTLA-4 inhibitors.
In partnership with Moderna (MRNA - Free Report) , Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) in combination with Keytruda for patients with certain types of melanoma and non-small cell lung cancer (NSCLC). Merck and Moderna are conducting pivotal phase III studies on V940, in combination with Keytruda, for earlier-stage and adjuvant NSCLC and adjuvant melanoma.
Merck is also developing a subcutaneous formulation of Keytruda that can extend its patent life. This formulation is under review in the United States and an FDA decision is expected in September.
While Keytruda continues to drive Merck’s growth, the company’s heavy dependence on the drug remains a concern.
Also, competitive pressure might increase for Keytruda in the near future. In 2024, Summit Therapeutics (SMMT - Free Report) reported positive data from a phase III study (conducted in China by partner Akeso) in patients with locally advanced or metastatic NSCLC, in which its lead pipeline candidate, ivonescimab, a dual PD-1 and VEGF inhibitor, outperformed Keytruda. Summit believes iivonescimab has the potential to replace Keytruda as the next standard of care across multiple NSCLC settings.
Though Keytruda is set to face loss of exclusivity in 2028, its sales are expected to stay strong until then.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have lost 15.3% compared with the industry’s decrease of 2.8%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 9.01 forward earnings, lower than 14.45 for the industry and its 5-year mean of 12.76.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has increased from $8.85 per share to $8.92, while the same for 2026 has decreased from $9.65 to $9.59 over the past 30 days.
Image: Bigstock
Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
Key Takeaways
Merck’s (MRK - Free Report) strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s pharmaceutical sales during the first half of 2025.
Keytruda, approved for several types of cancers, has played an instrumental role in driving Merck’s steady revenue growth over the past few years.
Keytruda generated sales of $15.16 billion in the first half of 2025, up almost 7% year over year. The drug remains a key driver of Merck’s top-line growth. Our model estimates full-year 2025 sales for Keytruda to be $32.2 billion, suggesting an increase of 9.2% year over year.
The drug’s sales are gaining from rapid uptake across earlier-stage indications, mainly early-stage non-small cell lung cancer. Continued strong momentum in metastatic indications is also boosting sales growth. The company expects continued growth from Keytruda, particularly in early lung cancer.
Per management, Keytruda will remain a key revenue driver for the company in the second half of 2025, along with the Animal Health business and new product launches like Winrevair and Capvaxive. However, weaker Gardasil sales in China and Japan will partly offset gains.
MRK Eyes Keytruda's Long-Term Growth Amid Upcoming Patent Loss
With Keytruda set to face patent loss in 2028, Merck is working on different strategies to drive its long-term growth. The company is advancing innovative immuno-oncology combinations, such as pairing Keytruda with LAG3 and CTLA-4 inhibitors.
In partnership with Moderna (MRNA - Free Report) , Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) in combination with Keytruda for patients with certain types of melanoma and non-small cell lung cancer (NSCLC). Merck and Moderna are conducting pivotal phase III studies on V940, in combination with Keytruda, for earlier-stage and adjuvant NSCLC and adjuvant melanoma.
Merck is also developing a subcutaneous formulation of Keytruda that can extend its patent life. This formulation is under review in the United States and an FDA decision is expected in September.
While Keytruda continues to drive Merck’s growth, the company’s heavy dependence on the drug remains a concern.
Also, competitive pressure might increase for Keytruda in the near future. In 2024, Summit Therapeutics (SMMT - Free Report) reported positive data from a phase III study (conducted in China by partner Akeso) in patients with locally advanced or metastatic NSCLC, in which its lead pipeline candidate, ivonescimab, a dual PD-1 and VEGF inhibitor, outperformed Keytruda. Summit believes iivonescimab has the potential to replace Keytruda as the next standard of care across multiple NSCLC settings.
Though Keytruda is set to face loss of exclusivity in 2028, its sales are expected to stay strong until then.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have lost 15.3% compared with the industry’s decrease of 2.8%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 9.01 forward earnings, lower than 14.45 for the industry and its 5-year mean of 12.76.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has increased from $8.85 per share to $8.92, while the same for 2026 has decreased from $9.65 to $9.59 over the past 30 days.
Image Source: Zacks Investment Research
MRK's Zacks Rank
Merck currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.